Well-Balanced: Akero Therapeutics (AKRO) Reports Encouraging NASH Trial Data
Akero Therapeutics Inc.’s (AKRO) phase IIa study of its investigational drug AKR-001 in patients with biopsy-confirmed nonalcoholic steatohepatitis, or NASH, has met the primary endpoint. In the study, dubbed BALANCED, all AKR-001 dose groups, say 28mg, 50 mg, and 70 mg, met the primary endpoint, with statistically significant absolute reductions in liver fat of 12-14% at Week 12. Similarly, all […]
Read more